Clinical trial NCT04282824: Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer
Official title: Evaluation by 68Ga-PSMA-11 PET Imaging of Monosodium Glutamate as a Potential Agent for Salivary Gland Protection Under PSMA-targeted Alpha-therapy: a Randomized Pilot Imaging Research Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Prostate Carcinoma
Lead sponsor: Jonsson Comprehensive Cancer Center
Sponsor class: OTHER
First posted: 2020-02-25
Enrollment: 14
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: This phase I trial studies the impact of monosodium glutamate (MSG) on 68GA-PSMA-11 PET/CT in decreasing the salivary glands uptake in patients with prostate cancer. Prostate specific membrane antigen (PSMA) is a molecule that is overexpressed by the prostate cancer cells. 68GA-PSMA-11 is an imaging radioactive drug that can target this molecule in tissues for imaging and therapy of prostate cancer. Food substances, such as monosodium glutamate, may reduce salivary gland uptake of 68GA-PSMA-11. Ultimately, giving MSG may reduce potential harm and injury to the salivary glands in patients with prostate cancer treated with PSMA-targeted molecular radiotherapy.

Detailed description: PRIMARY OBJECTIVE:

I. To determine the effect of monosodium glutamate (MSG) administration (glutamate supplementation) on the salivary gland uptake of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11).

SECONDARY OBJECTIVES:

I. To determine the effect of MSG administration on renal 68Ga-PSMA-11 uptake. II. To determine the effect of MSG administration on tumor 68Ga-PSMA-11 uptake. III. To determine if 68GA-PSMA-11 is excreted in the saliva. IV. Safety of MSG administration both oral ingestion and oral-salivary stimulation.

OUTLINE: Patients are randomized to 1 of 2 arms.

Arm I: Patients receive gallium Ga 68-labeled PSMA-11 intravenously (IV) and undergo a positron emission tomography (PET)/computed tomography (CT) scan on day 1. Within 2 weeks (days 2-14), patients receive MSG orally (PO) over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.

Arm II: Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.

Eligibility criteria: Inclusion Criteria:

* Patient volunteer to undergo 2 PSMA PET/CT scans within 14 days
* Histopathologically proven prostate cancer (PCa)
* PSMA PET/CT indicated for :

  * Initial staging before definitive therapy
  * Biochemical recurrence localization
  * Metastatic disease re-staging
* Ability to understand a written informed consent document and the willingness to sign it
* Ability to ingest 300 mL of fluid across 10 minute period

Exclusion Criteria:

* Prior salivary gland surgery or radiation therapy
* Prior history or current salivary gland disease
* Unable to lie flat, still or tolerate a PET scan
* Unable to follow the salivary flow stimuli administration regimen
* Unable to follow the glutamate supplementation administration regimens
* Asthma
* Severe uncontrolled hypertension (systolic blood pressure above 140 mm Hg and diastolic blood pressure above 90 mm Hg, or systolic blood pressure above 180 mm Hg, or diastolic blood pressure above 110 mg Hg). Patients with controlled hypertension under medication are eligible
* Sodium/salt restricted diet due to other medical conditions
* History of severe asthma that has led to hospitalizations or emergency room visits
* History of severe contraindications to MSG consumption including severe headaches, migraines or other intolerance
* Change to treatment administered between time of baseline scan and MSG scan

Primary outcomes:
measure: Salivary gland uptake of gallium Ga 68-labeled PSMA-11 (68Ga-PSMA-11)
timeFrame: 2 measurements within 2 to 14 days maximum (on positron emission tomography [PET]1 and PET2)
Secondary outcomes:
measure: Renal 68Ga-PSMA-11 uptake
timeFrame: 2 measurements within 2 to 14 days maximum (on PET1 and PET2)
measure: Tumor 68Ga-PSMA-11 uptake
timeFrame: 2 measurements within 2 to 14 days maximum (on PET1 and PET2)
measure: Saliva radioactivity concentration
timeFrame: 2 measurements within 2 to 14 days maximum (on PET1 and PET2)
measure: Incidence of adverse events of MSG administration
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: UCLA / Jonsson Comprehensive Cancer Center
state: California
Study officials:
affiliation: UCLA / Jonsson Comprehensive Cancer Center
name: Jeremie Calais, M.D.
role: PRINCIPAL_INVESTIGATOR
References: